UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

UBS analyst Alice Nettleton has initiated coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating. The firm has set a price target of $14 for the company's stock.